Amir Amedi

Remepy is Pioneering Hybrid Drugs™. We believe that in the future, software applications will become an integral part of treatments offered by Pharma companies in the form of Hybrid Drugs™. These will include both a software component and a traditional drug component - influencing patients via Hybrid Mechanisms of Action™. Remepy’s Digital Molecules™ are designed to be the software components within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug. The Digital Molecules™ enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine Remepy’s Digital Molecule™ and traditional drug components.